Jantoven

Quick links to important sections

Jantoven

Method of action: Anticoagulant

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Jantoven

Quick Facts

Property Description
Active ingredient Warfarin Sodium
Form Oral tablet
Pharmacological class Vitamin K antagonist (VKA)
General purpose Reduce blood clotting ability
Origin Synthetic 4-hydroxycoumarin derivative

What is Jantoven? Defining the Anticoagulant

Jantoven is a prescription-only medication that acts as an anticoagulant, commonly known as a blood thinner. Its active ingredient, Warfarin Sodium, is chemically defined as a synthetic 4-hydroxycoumarin derivative and belongs to the pharmacological class of Vitamin K antagonists (VKAs). This VKA status differentiates it from newer agents by interfering with the entire Vitamin K cycle required to activate multiple essential clotting factors (II, VII, IX, and X). This mechanism, which has been clinically recognized for decades for its stability, prevents the body from utilizing necessary components required for normal clotting.

Composition and Pharmaceutical Form

Jantoven is manufactured for oral administration as a single-ingredient product in the form of a solid oral tablet. The active substance is administered as a racemic mixture, meaning the compound contains both S-warfarin and R-warfarin, which the body processes at different rates. The tablet formulation includes necessary inactive excipients to ensure consistent absorption, making it suitable for long-term outpatient therapy. Jantoven is one of several branded and generic products containing Warfarin Sodium and is recognized for its comprehensive range of tablet strengths designed to assist with precise dose titration.

The General Purpose of Warfarin Therapy

The general purpose of Jantoven therapy is to significantly reduce the blood's ability to clot, thereby lessening the formation of potentially dangerous blood vessel blockages. By blocking the regeneration of Vitamin K in the liver, the medication effectively slows down the blood clotting timeline. The pharmacological profile of Warfarin defines it as an essential antithrombotic agent for therapeutic management. This action serves the primary goal of maintaining adequate fluidity and flow in the circulatory system, typically used to address conditions where the risk of abnormal clot formation is high.

Regulatory References

  1. Warfarin Mechanism (NIH StatPearls)
  2. Warfarin Drug Profile (NIH)

What side effects are possible with Jantoven?

Possible Side Effects and Safety Information

Jantoven's official safety profile is primarily defined by the inherent risk of hemorrhage (bleeding), which is classified in regulatory documents as a common or very common adverse reaction and is the principal safety concern.

Category Officially Documented Safety Details
Serious Adverse Reactions Major or fatal hemorrhage (including intracranial bleeding) is documented. Rare but serious tissue-related reactions include Warfarin-induced skin necrosis, purple toes syndrome, and calciphylaxis (a severe vascular calcification) [EMA SmPC].
System-Organ Classes Adverse effects are officially categorized across multiple body systems, including Blood and Lymphatic System Disorders (e.g., bleeding, anemia), Gastrointestinal Disorders (e.g., nausea, vomiting, diarrhea), Hepatobiliary Disorders (e.g., elevated liver enzymes), and Skin and Subcutaneous Tissue Disorders [FDA Label].
Time-Related Patterns Warfarin-induced skin necrosis is typically documented as occurring relatively early in the course of therapy, usually between 3 and 10 days after initiation of treatment.
Population-Specific Risks The risk of major bleeding is documented as higher in older adults and patients with renal impairment. The medicine is a known teratogen associated with Warfarin Embryopathy and is generally contraindicated during pregnancy [FDA Label].

The regulatory framework specifies that the risk of bleeding is dependent on the level of anticoagulation achieved. Furthermore, Jantoven is officially contraindicated in conditions associated with high hemorrhage risk, such as severe uncontrolled hypertension, recent major surgery, and severe hepatic impairment.

This structure ensures the safety profile is communicated with the necessary high-level precision, focusing only on the official classifications and documented risks found in government regulatory texts.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Warfarin Sodium (Jantoven) results in excessive anticoagulation, a condition officially documented to lead to various forms of bleeding. Manifestations described in regulatory prescribing information include blood in the urine (hematuria), blood in the stool (melena), excessive bruising, petechiae, and an unexplained drop in hemoglobin.

The most serious outcomes of overdose are the risk of major or fatal bleeding and, specifically, intracranial hemorrhage. Official labeling notes that older adults (age ge 65) are a population identified as having a higher risk of severe bleeding complications with excessive anticoagulation.

Required Emergency Actions

Immediate medical attention must be sought for any suspected overdose or for any bleeding that will not stop. It is mandated to contact emergency services immediately if an individual experiences signs of collapse, trouble breathing, or a seizure, as stated in government guidance.

Treatment management is guided by the International Normalized Ratio (INR) level and the presence of active bleeding. The specific reversal agent described in regulatory information is Vitamin K1 (Phytomenadione). For life-threatening hemorrhage, urgent procedural steps include administering coagulation factors, such as Prothrombin Complex Concentrate (PCC) or fresh frozen plasma, along with discontinuing Jantoven therapy.

Therapeutic Uses of Jantoven

What Jantoven Treats: Main Uses and Benefits

Jantoven (warfarin) is a medicine used to help manage the risk of blood clot formation in various clinical settings. This medicine is commonly used to help with conditions where functional stability becomes affected, offering support for symptomatic management. The application of this medicine is relevant in contexts involving: Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), atrial fibrillation, and mechanical heart valve replacement.

This medicine is applied across domains where additional symptomatic support is needed, such as in situations involving sudden or fluctuating symptom clusters. This medication may assist with managing symptoms that interfere with daily comfort. It is considered relevant during phases when symptoms become more noticeable, offering supportive relief that helps patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Systemic Imbalance

Jantoven is relevant for conditions marked by increased physiological stress, assisting with maintaining functional stability during symptomatic phases.

Regulatory References

  1. U.S. Food and Drug Administration Drug Labeling

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed:

  • Adults with labeled conditions, such as deep vein thrombosis (DVT) or atrial fibrillation.
  • Breastfeeding women, as official regulatory documents state warfarin is not detected in human milk.

Populations for whom use is contraindicated:

  • Pregnancy is an absolute contraindication, due to high fetal risk, with the only formal exception being conditional use for women with mechanical heart valves.
  • Patients with active bleeding (e.g., gastrointestinal tract), hemorrhagic tendencies, or specific conditions like malignant hypertension or bacterial endocarditis.
  • Individuals with recent or contemplated surgery of the central nervous system or eye, or those undergoing spinal or major regional block anesthesia.

Age and Condition-Related Eligibility Rules

  • Pediatric Patients: Safety and effectiveness have not been established in this age group.
  • Older Adults (Age ≥65): Use is permitted, but this population is explicitly identified by regulators as having a higher risk of major bleeding.
  • Organ Impairment: Use requires caution in patients with hepatic (liver) or severe renal (kidney) impairment, as these conditions may potentiate the effect of the medicine.
  • Genetic Factors: Eligibility may be restricted by genetic variations in CYP2C9 or VKORC1, which necessitate a lower initial dose to ensure safe initiation.

What should I know about interactions with other medicines?

Jantoven (warfarin sodium) has numerous documented interactions that can alter its anticoagulant effect, potentially leading to major or fatal bleeding, a risk highlighted in official warnings. The primary concern is the simultaneous use of other agents that increase bleeding risk. This includes Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Antiplatelet Agents (like aspirin and clopidogrel), and certain Antidepressants (specifically Serotonin Reuptake Inhibitors or SRIs).

The drug’s effect is also significantly influenced by the hepatic cytochrome P450 enzyme system. Inhibitors of CYP2C9, CYP1A2, and CYP3A4 (e.g., amiodarone, metronidazole, fluconazole) can potentiate Jantoven's action, causing the International Normalized Ratio (INR) to increase. Conversely, inducers of these enzymes (e.g., rifampin, carbamazepine, St. John's wort) may decrease its effect. Many Antibiotics and Antifungal agents are known to interact via these mechanisms or by altering gut flora.

Dietary intake is also critical; Jantoven’s action is antagonized by Vitamin K. Therefore, patients must maintain a consistent, not excessive, intake of foods rich in Vitamin K, such as leafy green vegetables. Any initiation, cessation, or change in dose for prescription, over-the-counter medicines, or herbal supplements must be carefully monitored with frequent INR testing.

Mechanism of Action

Jantoven's active ingredient, warfarin, acts as an anticoagulant exclusively by intervening in the synthesis of functional coagulation factors, which establishes a reduced systemic coagulation capacity.

Key Mechanism: Inhibiting the Vitamin K Recycling Pathway

Jantoven's mechanism begins in the liver, where it acts as a competitive inhibitor of the enzyme Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1). This blockade prevents the essential recycling of Vitamin K back into its active cofactor form ( KH2), which is required for the gamma-carboxylation of coagulation proteins. This mechanism targets the supply of the cofactor, causing newly synthesized coagulation factors to possess reduced biological function.

Molecular Consequence: Synthesis of Inactive Clotting Factors

Due to the depletion of the active Vitamin K cofactor, the liver synthesizes undercarboxylated (inactive) forms of the pro-coagulant factors II, VII, IX, and X, as well as the natural anticoagulant proteins C and S. The release of these inactive proteins into the bloodstream diminishes the total pool of functional factors, which alters the functionality of the entire coagulation cascade.

Physiological Outcome: Mechanism-Linked Onset and Constraint

The establishment of the full physiological alteration—a stable reduction in pro-coagulant activity—is inherently delayed because the drug must wait for existing, active clotting factors (especially Factor II, Prothrombin) to clear from circulation. This onset constraint is a direct consequence of the drug's mechanism, which focuses on preventing new synthesis rather than neutralizing existing factors or dissolving existing clots.

Dosage and Administration Information

Jantoven (warfarin sodium) is administered exclusively through the oral route as a tablet, which is available in nine different strengths to allow for precise adjustment of the dose. The fundamental principle of its use is individualized dosing, where the daily amount is determined by the patient's International Normalized Ratio (INR), a laboratory measure of clotting time.

Therapy is initiated with a typical daily starting dose of 2 mg to 5 mg, though routine use of high initial doses is generally avoided. The subsequent maintenance dose, which usually falls in the range of 2 mg to 10 mg once daily, is adjusted to keep the INR within the prescriber's specified therapeutic range. This adjustment process often requires frequent INR monitoring upon starting therapy and periodically thereafter.

The medication is taken once daily at the same time each day to maintain consistent blood levels. The tablet may be consumed either with or without food. If a dose is missed, the protocol is to take it as soon as possible on the same day, but patients must not double the dose the following day.

Specific administration principles address certain populations: for instance, older adults may require a lower starting and maintenance dose due to increased sensitivity. Additionally, dosing for pediatric patients or those with hepatic impairment is also highly individualized and guided by INR response. The duration of use is often long-term or indefinite, depending on the underlying condition.

Recent Clinical Evidence

Research Evidence / Overview of Studies


The Drug's Action in Studies

Research has studied the drug's action. Studies have investigated the drug's studied action profile, focusing on its role as a vitamin K antagonist.

Clinical Study Findings

Short-Term Evaluation

Studies evaluated the drug in the context of acute therapeutic needs, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). Research focused on evaluating outcomes related to the duration and extent of reducing clotting risk in these conditions.

  • Evaluation Context: Studies typically assessed the drug in the context of initiating anticoagulation treatment.
  • Observed Timing: Researchers measured the observed changes in blood clotting indicators (like the International Normalized Ratio, or INR) and the duration of those changes.

Management of Long-Term Conditions

Research investigated the drug in relation to preventing systemic embolism in patients with atrial fibrillation (AF) and following mechanical heart valve placement. Evidence for long-term use requires continuous monitoring and risk assessment.


Combination Use and Observed Events

Drug-Drug Interactions

Research examined the interaction when the drug was administered with other medications. Due to its mechanism, numerous interactions were studied, impacting dosage.

Adverse Event Profile

Studies reported on the incidence and severity of observed adverse events, including major and minor bleeding episodes.

Quality of Life

Researchers assessed patient-reported quality of life measures during long-term use, considering the burden of frequent monitoring.

Comparative Research

Research explored study endpoints when the drug was investigated alongside newer oral anticoagulants. Studies focused on measuring comparable effects and comparing adverse event reports between the treatment groups. It is not yet clear whether any difference in long-term safety exists across all populations.

Key Studies & References

  1. Meta-analysis of randomized controlled trials comparing new oral anticoagulants with warfarin in patients with atrial fibrillation

Frequently Asked Questions (FAQ)

Common questions about Jantoven (FAQ)

Q: How quickly should Jantoven start working?

Official product information describes that the initial change in clotting factors may be measurable within 24 hours of administration. However, the full anticoagulant effect is delayed. This is because the medicine works by preventing the synthesis of new clotting factors, and this peak effect typically occurs 72 to 96 hours after the drug is first taken.


Q: Are there any foods I have to completely avoid while taking Jantoven?

Regulatory documents state that official advice is to avoid consuming certain fruit juices while taking this medication, as they may interact with its effect. Specifically, juices such as cranberry, grapefruit, noni, and pomegranate juice are listed.


Q: Can Jantoven be affected by other things I drink, like cranberry juice or alcohol?

Official guidance is to avoid the consumption of alcohol while taking this medicine. Additionally, regulatory sources indicate that cranberry juice is among the beverages that may interact with the way Jantoven works in the body.


Q: What are the signs of major or serious bleeding while taking Jantoven?

Official patient information lists several important signs that indicate a serious bleeding problem. These signs include visible bleeding such as pink or brown urine, red or black stools, or coughing up or vomiting blood.


Q: What does an unusually severe headache while on Jantoven signify?

Official materials advise that patients should contact their healthcare provider right away if they experience headaches, dizziness, or weakness. These symptoms are listed as signs of potential bleeding problems that should be reported.


Q: Is it normal to bruise more easily while taking Jantoven?

Official regulatory information lists unusual bruising as a potential sign of bleeding problems that are listed for patients to be aware of. This refers to bruises that develop without a known injury or that appear to grow in size.


Q: Can Jantoven cause hair loss or changes to the skin?

Serious and rare skin-related reactions associated with warfarin therapy include Warfarin-induced skin necrosis and purple toes syndrome. Hair loss is generally not explicitly listed among the common adverse reactions in official regulatory sections.


Q: What is 'purple toes syndrome' and is it a side effect of Jantoven?

Purple toes syndrome is a rare but serious reaction documented as associated with the use of warfarin. This condition involves pain and a purple or dark discoloration in the toes. Patients are advised that these signs should be immediately reported to a healthcare provider.


Q: How often do INR blood tests typically need to be performed?

According to official dosage information, the International Normalized Ratio (INR) should be monitored daily or every few days when starting therapy until the prescribed target range is achieved. For long-term use, monitoring frequency may be appropriate every 4 to 6 weeks or longer, depending on the individual.


Q: What happens if the INR level is too high or too low?

The INR level is used to gauge the blood’s clotting time. Regulatory warnings indicate that an INR greater than 4.0 is associated with a higher risk of bleeding. Conversely, an INR that is too low means the patient may be at higher risk for clots forming.


Q: Is Jantoven available under a different name?

Yes, Jantoven is one of the brand names for the active ingredient, warfarin sodium. Coumadin is also listed in official patient information as another brand name for the same drug.


Q: Is there a difference between Jantoven and Coumadin?

Coumadin and Jantoven are both the brand names for the same active drug, warfarin. While they are expected to work the same way, official guidance notes that minor differences in their formulations may exist.


Q: Can Jantoven interact with marijuana or cannabis use?

Available interaction data from regulatory sources indicate that marijuana (cannabis) may increase the blood levels and effects of warfarin. This is a condition under which closer INR monitoring may be indicated if use is started or stopped.


Q: Is it true that different manufacturers' versions of warfarin can affect my INR results?

Official patient counseling materials emphasize that it is important to know what company makes your warfarin so that blood tests are not affected. Regulatory bodies have stated that generic warfarin products are chemically interchangeable.


Q: What should I tell my dentist or surgeon before a procedure if I take Jantoven?

Official patient information advises users to tell all of their healthcare providers, including dentists and surgeons, that they take Jantoven. Patients are also advised to wear or carry information indicating that they are taking the medicine.


Q: Can Jantoven be used to prevent a first stroke?

Official documentation states that Jantoven is indicated for the prophylaxis (prevention) of systemic embolism, which includes stroke, associated with certain underlying conditions, such as atrial fibrillation.


Q: Why does illness, like a fever or diarrhea, require a call to the doctor when taking Jantoven?

Official patient information advises reporting these conditions, such as diarrhea, an infection, or a fever, to a healthcare provider right away. These conditions can influence the body's clotting ability and may alter the dose or effect of the medicine, which requires review.


Q: What type of physical activity or sports are safe to do while on Jantoven?

Regulatory patient materials advise avoiding any activity or sport that may cause a serious injury or excessive bleeding. This warning stems from the drug's inherent safety risk of hemorrhage.


Q: Should I wear a medical alert bracelet if I am taking Jantoven?

Official guidance recommends wearing or carrying information that indicates a patient takes Jantoven. This practice helps ensure that emergency medical personnel are aware of the medication immediately.


Q: Can Jantoven interact with nutritional supplements like Boost or Ensure?

Official regulatory text advises caution with certain nutritional products. Specifically, caution is advised regarding enteral (tube) feedings and avoiding soy protein formulas to minimize potential interaction with Jantoven.


Q: Does Jantoven affect the use of hormonal birth control?

The drug's active ingredient is processed by the same liver enzyme system (CYP3A4) that metabolizes many hormonal contraceptives. Interaction data indicates that the effectiveness of hormonal birth control may be reduced when co-administered, requiring patient awareness.


Q: Does Jantoven have a Black Box Warning, and what does it mean?

Yes, Jantoven includes a BOXED WARNING, a prominent feature on the official label. This warning advises that the drug can cause major or fatal bleeding, which is the most serious risk associated with its use.


Q: How long does Jantoven stay in my system after I stop taking it?

The way the body processes the drug means that its effect can last for a long period. The effective half-life of the active ingredient ranges from 20 to 60 hours. The terminal half-life after a single dose is approximately one week.


Q: Is it safe to use topical products, like aloe gel, while on Jantoven?

Official regulatory warnings advise that some medications that are applied to the skin (topical products) can interact with warfarin, potentially affecting its action in the body.


Q: Can taking Jantoven cause excessive swelling or joint pain?

Pain, swelling, or discomfort are listed in the official patient information as signs of bleeding problems. These symptoms should be reported to a healthcare provider right away.


Q: What are the warning signs of internal bleeding other than visible blood?

According to official patient materials, non-visible signs of potential internal bleeding include headaches, dizziness, or weakness. Other listed signs include unusual pain, swelling, or discomfort.

How should Jantoven be stored and disposed of?

How to Store and Dispose of Jantoven (Warfarin Sodium)

Jantoven tablets must be stored at Controlled Room Temperature, specifically defined as 20 to 25 C (68 to 77 F), and must be protected from both light and moisture. The medicine must be kept in a tightly closed container.

Storage Requirement Official Condition
Temperature 20 to 25 C (68 to 77 F)
Container Keep in a tightly closed container
Protection Keep out of the light and moisture
Child Safety Store out of the reach of children

For disposal, unused or outdated Jantoven should be discarded according to official instructions, preferably utilizing an authorized drug take-back program. If a take-back program is unavailable, follow the procedure of mixing the product with an undesirable substance before placing it in the household trash. Pregnant women should not handle crushed or broken Jantoven tablets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Jantoven found in:

A-Z Index: